Detection of Measurable Residual Disease Biomarkers in Extracellular Vesicles from Liquid Biopsies of Multiple Myeloma Patients-A Proof of Concept

被引:8
作者
Bergantim, Rui [1 ,2 ,3 ,4 ]
da Silva, Sara Peixoto [1 ,2 ]
Polonia, Barbara [1 ,2 ]
Barbosa, Melanie A. G. [1 ,2 ]
Albergaria, Andre [1 ,5 ]
Lima, Jorge [1 ,5 ]
Caires, Hugo R. [1 ,2 ]
Guimaraes, Jose E. [1 ,2 ,3 ,4 ,6 ]
Vasconcelos, M. Helena [1 ,2 ,7 ]
机构
[1] Univ Porto, I3S Inst Invest & Inovacao Saude, P-4200135 Porto, Portugal
[2] Univ Porto, Canc Drug Resistance Grp, IPATIMUP Inst Mol Pathol & Immunol, P-4200135 Porto, Portugal
[3] Hosp Ctr Sao Joao, Clin Hematol, P-4200319 Porto, Portugal
[4] Univ Porto, Clin Hematol, FMUP Fac Med, P-4200319 Porto, Portugal
[5] Univ Porto, I3S Inst Invest & Inovacao Saude, Res Innovat Unit, Translat Res & Ind Partnerships Off, P-4200135 Porto, Portugal
[6] Inst Univ Ciencias Saude Cooperat Ensino Super Po, P-4585116 Gandra Paredes, Portugal
[7] Univ Porto, Dept Biol Sci, FFUP Fac Pharm, P-4050313 Porto, Portugal
关键词
multiple myeloma; extracellular vesicles; measurable residual disease; liquid biopsy; CIRCULATING TUMOR-CELLS; NEXT-GENERATION FLOW; CONSENSUS GUIDELINES; SURVIVAL OUTCOMES; DRUG-RESISTANCE; EXOSOMES; MICROVESICLES; EXPRESSION; PLASMA; LENALIDOMIDE;
D O I
10.3390/ijms232213686
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Monitoring measurable residual disease (MRD) is crucial to assess treatment response in Multiple Myeloma (MM). Detection of MRD in peripheral blood (PB) by exploring Extracellular Vesicles (EVs), and their cargo, would allow frequent and minimally invasive monitoring of MM. This work aims to detect biomarkers of MRD in EVs isolated from MM patient samples at diagnosis and remission and compare the MRD-associated content between BM and PB EVs. EVs were isolated by size-exclusion chromatography, concentrated by ultrafiltration, and characterized according to their size and concentration, morphology, protein concentration, and the presence of EV-associated protein markers. EVs from healthy blood donors were used as controls. It was possible to isolate EVs from PB and BM carrying MM markers. Diagnostic samples had different levels of MM markers between PB and BM paired samples, but no differences between PB and BM were found at remission. EVs concentration was lower in the PB of healthy controls than of patients, and MM markers were mostly not detected in EVs from controls. This study pinpoints the potential of PB EVs from MM remission patients as a source of MM biomarkers and as a non-invasive approach for monitoring MRD.
引用
收藏
页数:22
相关论文
共 108 条
[71]   Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma A Meta-analysis [J].
Munshi, Nikhil C. ;
Avet-Loiseau, Herve ;
Rawstron, Andy C. ;
Owen, Roger G. ;
Child, J. Anthony ;
Thakurta, Anjan ;
Sherrington, Paul ;
Samur, Mehmet Kemal ;
Georgieva, Anna ;
Anderson, Kenneth C. ;
Gregory, Walter M. .
JAMA ONCOLOGY, 2017, 3 (01) :28-35
[72]   Ultrafiltration with size-exclusion liquid chromatography for high yield isolation of extracellular vesicles preserving intact biophysical and functional properties [J].
Nordin, Joel Z. ;
Lee, Yi ;
Vader, Pieter ;
Maeger, Imre ;
Johansson, Henrik J. ;
Heusermann, Wolf ;
Wiklander, Oscar P. B. ;
Hallbrink, Mattias ;
Seow, Yiqi ;
Bultema, Jarred J. ;
Gilthorpe, Jonathan ;
Davies, Tim ;
Fairchild, Paul J. ;
Gabrielsson, Susanne ;
Meisner-Kober, Nicole C. ;
Lehtio, Janne ;
Smith, C. I. Edvard ;
Wood, Matthew J. A. ;
Andaloussi, Samir E. L. .
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2015, 11 (04) :879-883
[73]   Role of Circulating Tumor DNA in Hematological Malignancy [J].
Ogawa, Miho ;
Yokoyama, Kazuaki ;
Imoto, Seiya ;
Tojo, Arinobu .
CANCERS, 2021, 13 (09)
[74]   Minimal Residual Disease Evaluation By Multiparameter Flow Cytometry and Next Generation Sequencing in the Forte Trial for Newly Diagnosed Multiple Myeloma Patients [J].
Oliva, Stefania ;
Genuardi, Elisa ;
Belotti, Angelo ;
Frascione, Pio Manlio Mirko ;
Galli, Monica ;
Capra, Andrea ;
Offidani, Massimo ;
Vozella, Federico ;
Zambello, Renato ;
Auclair, Daniel ;
Siniscalchi, Agostina ;
Yesil, Jennifer ;
Annibali, Ombretta ;
Kirsch, Ilan M. ;
Caltagirone, Simona ;
Jacob, Allison P. ;
Ballanti, Stelvio ;
Palmas, Angelo D. ;
Ledda, Antonio ;
Corradini, Paolo ;
Omede, Paola ;
Cavo, Michele ;
Musto, Pellegrino ;
Boccadoro, Mario ;
Gay, Francesca .
BLOOD, 2019, 134
[75]   Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma [J].
Oliva, Stefania ;
D'Agostino, Mattia ;
Boccadoro, Mario ;
Larocca, Alessandra .
FRONTIERS IN ONCOLOGY, 2020, 10
[76]   Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis [J].
Oliva, Stefania ;
Gambella, Manuela ;
Gilestro, Milena ;
Muccio, Vittorio Emanuele ;
Gay, Francesca ;
Drandi, Daniela ;
Ferrero, Simone ;
Passera, Roberto ;
Pautasso, Chiara ;
Bernardini, Annalisa ;
Genuardi, Mariella ;
Patriarca, Francesca ;
Saraci, Elona ;
Petrucci, Maria Teresa ;
Pescosta, Norbert ;
Liberati, Anna Marina ;
Caravita, Tommaso ;
Conticello, Concetta ;
Rocci, Alberto ;
Musto, Pellegrino ;
Boccadoro, Mario ;
Palumbo, Antonio ;
Omede, Paola .
ONCOTARGET, 2017, 8 (04) :5924-5935
[77]   Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma [J].
Paiva, Bruno ;
Puig, Noemi ;
Cedena, Maria-Teresa ;
Rosinol, Laura ;
Cordon, Lourdes ;
Vidriales, Maria-Belen ;
Burgos, Leire ;
Flores-Montero, Juan ;
Sanoja-Flores, Luzalba ;
Lopez-Anglada, Lucia ;
Maldonado, Roberto ;
de la Cruz, Javier ;
Gutierrez, Norma C. ;
Calasanz, Maria-Jose ;
Martin-Ramos, Maria-Luisa ;
Garcia-Sanz, Ramon ;
Martinez-Lopez, Joaquin ;
Oriol, Albert ;
Blanchard, Maria-Jesus ;
Rios, Rafael ;
Martin, Jesus ;
Martinez-Martinez, Rafael ;
Sureda, Anna ;
Hernandez, Miguel-Teodoro ;
de la Rubia, Javier ;
Krsnik, Isabel ;
Moraleda, Jose-Maria ;
Palomera, Luis ;
Bargay, Joan ;
Van Dongen, Jacques J. M. ;
Orfao, Alberto ;
Mateos, Maria-Victoria ;
Blade, Joan ;
San-Miguel, Jesus F. ;
Lahuerta, Juan-Jose .
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (08) :784-+
[78]   Absence of both CD56 and CD117 expression on malignant plasma cells is related with a poor prognosis in patients with newly diagnosed multiple myeloma [J].
Pan, Ying ;
Wang, Huiping ;
Tao, Qianshan ;
Zhang, Cui ;
Yang, Dongdong ;
Qin, Hui ;
Xiong, Shudao ;
Tao, Lili ;
Wu, Fan ;
Zhang, Jiakui ;
Zhai, Zhimin .
LEUKEMIA RESEARCH, 2016, 40 :77-82
[79]   Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma [J].
Perrot, Aurore ;
Lauwers-Cances, Valerie ;
Corre, Jill ;
Robillard, Nelly ;
Hulin, Cyrille ;
Chretien, Marie-Lorraine ;
Dejoie, Thomas ;
Maheo, Sabrina ;
Stoppa, Anne-Marie ;
Pegourie, Brigitte ;
Karlin, Lionel ;
Garderet, Laurent ;
Arnulf, Bertrand ;
Doyen, Chantal ;
Meuleman, Nathalie ;
Royer, Bruno ;
Eveillard, Jean-Richard ;
Benboubker, Lotfi ;
Dib, Mamoun ;
Decaux, Olivier ;
Jaccard, Arnaud ;
Belhadj, Karim ;
Brechignac, Sabine ;
Kolb, Brigitte ;
Fohrer, Cecile ;
Mohty, Mohamad ;
Macro, Margaret ;
Richardson, Paul G. ;
Carlton, Victoria ;
Moorhead, Martin ;
Willis, Tom ;
Faham, Malek ;
Anderson, Kenneth C. ;
Harousseau, Jean-Luc ;
Leleu, Xavier ;
Facon, Thierry ;
Moreau, Philippe ;
Attal, Michel ;
Avet-Loiseau, Herve ;
Munshi, Nikhil .
BLOOD, 2018, 132 (23) :2456-2464
[80]   Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing [J].
Rasche, L. ;
Chavan, S. S. ;
Stephens, O. W. ;
Patel, P. H. ;
Tytarenko, R. ;
Ashby, C. ;
Bauer, M. ;
Stein, C. ;
Deshpande, S. ;
Wardell, C. ;
Buzder, T. ;
Molnar, G. ;
Zangari, M. ;
van Rhee, F. ;
Thanendrarajan, S. ;
Schinke, C. ;
Epstein, J. ;
Davies, F. E. ;
Walker, B. A. ;
Meissner, T. ;
Barlogie, B. ;
Morgan, G. J. ;
Weinhold, N. .
NATURE COMMUNICATIONS, 2017, 8